Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 1, 2000, Pages 337-345

  Lim, Howard J ^a,b   Masin, Dana ^b   Mcintosh, Natashia L ^b   Madden, Thomas D ^a   Bally, Marcel B ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RELEASE; FEMALE; HUMAN; HUMAN TISSUE; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MICE; MITOXANTRONE; NEOPLASM TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033957887     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Adlakha-Hutcheon G, Bally MB, Shew CR and Madden TD (1999) Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nature Biotechnol 17:775-779.
2. Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1086:29-36.
3. Bally MB, Masin D, Nayar R, Cullis PR and Mayer LD (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34:137-146.
4. Bally MB, Mayer LD, Hope MJ and Nayar R (1993) Pharmacodynamics of liposomal drug carriers: Methodological considerations, in Liposome Technology (Gregoriadis G ed) pp 27-41, CRC Press, Boca Raton, FL.
5. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR and Mayer LD (1990) Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023:133-139.
6. Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A and Schoch I (1988) A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6:1611-1620.
7. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A and Tannock IF (1998) Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points. J Clin Oncol 16:2272-2279.
8. Boman NL, Masin D, Mayer LD, Cullis PR and Bally MB (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 64:2830-2833.
9. Boman NL, Mayer LD and Cullis PR (1993) Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1152:253-258.
10. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA and Scherphof GL (1995) Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages, Int J Cancer 61:716-721.
11. Dukart G, Iatropoulos MJ and Yacobi A (1985) Comment on mitoxantrone. Drug Intell Clin. Pharm 19:216-218.
12. Durr FE (1984) Biologic and biochemical effects of mitoxantrone. Semin Oncol 11:3-10.
13. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM (1988) Identification and characterization of blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133:95-109.
14. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L and Senger DR (1991) Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278.
15. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203.
16. Gabizon A, Chemla M, Tzemach D, Horowitz AT and Goren D (1996) Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 3:391-398.
17. Hope MJ, Bally MB, Webb G and Cullis PR (1985) Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55-65.
18. Lee RJ and Low PS (1993) Delivery of liposomes in cultured KB cells via folate receptor mediated endocytosis. J Biol Chem 26:24847-24854.
19. Lee RJ and Low PS (1994) Folate mediated tumor cell targeting of liposome entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144.
20. Lim HJ (1999) Role of Liposome-mediated Drug Delivery and Drug Release in Determining the Therapeutic Activity of Liposomal Formulations of Mitoxantrone. Ph.D. Thesis, University of British Columbia, Vancouver, Canada.
21. Lim HJ, Masin D, Madden TD and Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. JPharmacol Exp Ther 281:566-573.
22. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR and Bally MB (1995) Accumulation of protein-coated liposomes in an extravascular site: Influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275:1177-1184.
23. Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinsih LW and Cullis PR (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem Phys Lipids 53:37-46.
24. Mayer LD, Bally MB, Cullis PR, Wilson SL and Emerman JT (1990) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53:183-190.
25. Mayer LD, Bally MB, Hope MJ and Cullis PR (1985) Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816:294-302.
26. Mayer LD, Cullis PR and Bally MB (1994) The use of transmembrane pH gradient-driven drug encapsulation in the pharmacodynamic evaluation of liposomal doxorubicin. J Liposome Res 4:529-553.
27. Mayer LD, Hope MJ and Cullis PR (1986) Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 859:161-168.
28. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR and Bally MB (1993) Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33:17-24.
29. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922-5930.
30. Neidhart JA, Gochnour D, Roach R, Hoth D and Young D (1986) A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4:672-677.
31. Proffitt RT, Williams LE, Presant CA, Tin GW, Uliana JA, Gamble RC and Baldeschwieler JD (1983) Tumor-imaging potential of liposomes loaded with In-111-NTA: Biodistribution in mice. J Nucl Med 24:45-51.
32. Scherphof GL, Kamps JAAM and Koning GA (1997) In vivo targeting of surface-modified liposome to metastatically growing colon carcinoma cells and sinusoidal endothelial cells in the rat liver. J Liposome Res 7:419-432.
33. Smith DC (1999) Chemotherapy for hormone refractory prostate cancer. Urol Clin N Am 26:323-331.
34. Smith IE, Stuart-Harris R, Pavlidis N, Bozek T (1983) Mitoxantrone (Novantrone) as a single agent and in combination chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rev 10 (Suppl B):37-40.
35. 3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett 111:104-106.
36. Storm G, Steerenberg PA, Emmen F, van Borssum Waalkes M and Crommelin DJ (1988) Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 965:136-145.
37. Tomayko MM and Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154.
38. Wang S, Lee RJ, Cauchon G, Gorenstein DG and Low PS (1995) Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA 92:3318-3322.
39. Weiss RB (1989) Mitoxantrone: Its development and role in clinical practice. Oncology 3:135-148.